Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.49 |
| ▸ | PPARD | Q03181 | 12/20 | 0.49 |
| ▸ | PPARG | P37231 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575408 | 0.95 | PPARA (0.47) | PPARAPPARDPPARGMEN1KMT2A | |
| SCHEMBL4575797 | 0.95 | PPARA (0.47) | PPARAPPARDPPARGGCGRGIPR | |
| SCHEMBL4575150 | 0.94 | PPARA (0.47) | PPARAPPARDPPARGGCGRGIPR | |
| SCHEMBL4575804 | 0.92 | PPARA (0.46) | PPARAPPARDPPARGMEN1KMT2A | |
| SCHEMBL4574610 | 0.90 | PPARA (0.56) | PPARAPPARDPPARGMEN1KMT2A | |
| SCHEMBL4575281 | 0.89 | PPARA (0.48) | PPARAPPARDPPARGKMT2AGCGR | |
| SCHEMBL4574779 | 0.89 | PPARA (0.50) | PPARAPPARDPPARGNPSR1 | |
| SCHEMBL4575152 | 0.89 | PPARA (0.50) | PPARAPPARDPPARG | |
| SCHEMBL4575181 | 0.88 | PPARA (0.51) | PPARAPPARDPPARG | |
| SCHEMBL4576168 | 0.87 | PPARA (0.49) | PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | PPARA 2/4885PPARD 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.